Search | Virtual Health Library

1.

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.

Chowdhury, Shrabanti; Kennedy, Jacob J; Ivey, Richard G; Murillo, Oscar D; Hosseini, Noshad; Song, Xiaoyu; Petralia, Francesca; Calinawan, Anna; Savage, Sara R; Berry, Anna B; Reva, Boris; Ozbek, Umut; Krek, Azra; Ma, Weiping; da Veiga Leprevost, Felipe; Ji, Jiayi; Yoo, Seungyeul; Lin, Chenwei; Voytovich, Uliana J; Huang, Yajue; Lee, Sun-Hee; Bergan, Lindsay; Lorentzen, Travis D; Mesri, Mehdi; Rodriguez, Henry; Hoofnagle, Andrew N; Herbert, Zachary T; Nesvizhskii, Alexey I; Zhang, Bing; Whiteaker, Jeffrey R; Fenyo, David; McKerrow, Wilson; Wang, Joshua; Schürer, Stephan C; Stathias, Vasileios; Chen, X Steven; Barcellos-Hoff, Mary Helen; Starr, Timothy K; Winterhoff, Boris J; Nelson, Andrew C; Mok, Samuel C; Kaufmann, Scott H; Drescher, Charles; Cieslik, Marcin; Wang, Pei; Birrer, Michael J; Paulovich, Amanda G.

Cell ; 186(16): 3476-3498.e35, 2023 08 03.

Article in English | MEDLINE | ID: mdl-37541199

2.

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.

Chowdhury, Shrabanti; Kennedy, Jacob J; Ivey, Richard G; Murillo, Oscar D; Hosseini, Noshad; Song, Xiaoyu; Petralia, Francesca; Calinawan, Anna; Savage, Sara R; Berry, Anna B; Reva, Boris; Ozbek, Umut; Krek, Azra; Ma, Weiping; da Veiga Leprevost, Felipe; Ji, Jiayi; Yoo, Seungyeul; Lin, Chenwei; Voytovich, Uliana J; Huang, Yajue; Lee, Sun-Hee; Bergan, Lindsay; Lorentzen, Travis D; Mesri, Mehdi; Rodriguez, Henry; Hoofnagle, Andrew N; Herbert, Zachary T; Nesvizhskii, Alexey I; Zhang, Bing; Whiteaker, Jeffrey R; Fenyo, David; McKerrow, Wilson; Wang, Joshua; Schürer, Stephan C; Stathias, Vasileios; Chen, X Steven; Barcellos-Hoff, Mary Helen; Starr, Timothy K; Winterhoff, Boris J; Nelson, Andrew C; Mok, Samuel C; Kaufmann, Scott H; Drescher, Charles; Cieslik, Marcin; Wang, Pei; Birrer, Michael J; Paulovich, Amanda G.

Cell ; 187(4): 1016, 2024 Feb 15.

Article in English | MEDLINE | ID: mdl-38364782

3.

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.

Yazinski, Stephanie A; Comaills, Valentine; Buisson, Rémi; Genois, Marie-Michelle; Nguyen, Hai Dang; Ho, Chu Kwen; Todorova Kwan, Tanya; Morris, Robert; Lauffer, Sam; Nussenzweig, André; Ramaswamy, Sridhar; Benes, Cyril H; Haber, Daniel A; Maheswaran, Shyamala; Birrer, Michael J; Zou, Lee.

Genes Dev ; 31(3): 318-332, 2017 02 01.

Article in English | MEDLINE | ID: mdl-28242626

4.

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.

Penson, Richard T; Ambrosio, Allison J; Whalen, Christin A; Krasner, Carolyn N; Konstantinopoulos, Panagiotis A; Bradley, Charles; Matulonis, Ursula A; Birrer, Michael J.

Oncologist ; 28(3): 252-257, 2023 03 17.

Article in English | MEDLINE | ID: mdl-36718018

5.

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Tewari, Krishnansu S; Sill, Michael W; Birrer, Michael J; Penson, Richard T; Huang, Helen; Moore, David H; Ramondetta, Lois M; Landrum, Lisa M; Oaknin, Ana; Reid, Thomas J; Leitao, Mario M; Michael, Helen E; Monk, Bradley J.

Gynecol Oncol ; 171: 141-150, 2023 04.

Article in English | MEDLINE | ID: mdl-36898292

6.

DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.

Chowdhury, Shrabanti; Wang, Ru; Yu, Qing; Huntoon, Catherine J; Karnitz, Larry M; Kaufmann, Scott H; Gygi, Steven P; Birrer, Michael J; Paulovich, Amanda G; Peng, Jie; Wang, Pei.

BMC Bioinformatics ; 23(1): 321, 2022 Aug 05.

Article in English | MEDLINE | ID: mdl-35931981

7.

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

Farley, John H; Brady, William E; O'Malley, David; Fujiwara, Keiichi; Yonemori, Kan; Bonebrake, Albert; Secord, Angeles Alvarez; Stephan, Jean-Marie; Walker, Joan L; Nam, Joo-Hyun; Birrer, Michael J; Gershenson, David M.

Gynecol Oncol ; 167(3): 423-428, 2022 Dec.

Article in English | MEDLINE | ID: mdl-36244829

8.

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

Swisher, Elizabeth M; Aghajanian, Carol; O'Malley, David M; Fleming, Gini F; Kaufmann, Scott H; Levine, Douglas A; Birrer, Michael J; Moore, Kathleen N; Spirtos, Nick M; Shahin, Mark S; Reid, Thomas J; Friedlander, Michael; Steffensen, Karina Dahl; Okamoto, Aikou; Sehgal, Vasudha; Ansell, Peter J; Dinh, Minh H; Bookman, Michael A; Coleman, Robert L.

Gynecol Oncol ; 164(2): 245-253, 2022 02.

Article in English | MEDLINE | ID: mdl-34906376

9.

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.

Campos, Susana; Matulonis, Ursula; Berlin, Suzanne; Horowitz, Neil; Liu, Joyce; Krasner, Carolyn; Hang, Lee; Zarwan, Corrine; Barry, William; Colella, Tina; Whalen, Christen; Shoni, Melina; Lundquist, Christine; Birrer, Michael J; Penson, Richard.

Int J Clin Oncol ; 27(12): 1881-1890, 2022 Dec.

Article in English | MEDLINE | ID: mdl-36344654

10.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

Monk, Bradley J; Colombo, Nicoletta; Oza, Amit M; Fujiwara, Keiichi; Birrer, Michael J; Randall, Leslie; Poddubskaya, Elena V; Scambia, Giovanni; Shparyk, Yaroslav V; Lim, Myong Cheol; Bhoola, Snehalkumar M; Sohn, Joohyuk; Yonemori, Kan; Stewart, Ross A; Zhang, Xiaoxi; Perkins Smith, Julia; Linn, Carlos; Ledermann, Jonathan A.

Lancet Oncol ; 22(9): 1275-1289, 2021 09.

Article in English | MEDLINE | ID: mdl-34363762

11.

Inhibition of Kpnß1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.

Chi, Ru-Pin Alicia; van der Watt, Pauline; Wei, Wei; Birrer, Michael J; Leaner, Virna D.

BMC Cancer ; 21(1): 106, 2021 Feb 02.

Article in English | MEDLINE | ID: mdl-33530952

12.

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).

Buechel, Megan E; Enserro, Danielle; Burger, Robert A; Brady, Mark F; Wade, Katrina; Secord, Angeles Alvarez; Nixon, Andrew B; Mirniaharikandehei, Seyedehnafiseh; Liu, Hong; Zheng, Bin; O'Malley, David M; Gray, Heidi; Tewari, Krishnansu S; Mannel, Robert S; Birrer, Michael J; Moore, Kathleen N.

Gynecol Oncol ; 161(2): 382-388, 2021 05.

Article in English | MEDLINE | ID: mdl-33712274

13.

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.

Krasner, Carolyn N; Campos, Susana M; Young, Chantay L; Chadda, Karan R; Lee, Hang; Birrer, Michael J; Horowitz, Neil S; Konstantinopoulos, Panagiotis A; D'Ascanio, Antonella M; Matulonis, Ursula A; Penson, Richard T.

Gynecol Oncol ; 162(3): 661-666, 2021 09.

Article in English | MEDLINE | ID: mdl-34243976

14.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Arend, Rebecca C; Davis, Allison M; Chimiczewski, Przemyslaw; O'Malley, David M; Provencher, Diane; Vergote, Ignace; Ghamande, Sharad; Birrer, Michael J.

Gynecol Oncol ; 156(2): 301-307, 2020 02.

Article in English | MEDLINE | ID: mdl-31870556

15.

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.

Betella, Ilaria; Turbitt, William J; Szul, Tomasz; Wu, Binghao; Martinez, Alba; Katre, Ashwini; Wall, Jaclyn A; Norian, Lyse; Birrer, Michael J; Arend, Rebecca.

Gynecol Oncol ; 157(3): 765-774, 2020 06.

Article in English | MEDLINE | ID: mdl-32192732

16.

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.

Arend, Rebecca C; Beer, Hannah M; Cohen, Yael C; Berlin, Suzanne; Birrer, Michael J; Campos, Susana M; Rachmilewitz Minei, Tamar; Harats, Dror; Wall, Jaclyn A; Foxall, McKenzie E; Penson, Richard T.

Gynecol Oncol ; 157(3): 578-584, 2020 06.

Article in English | MEDLINE | ID: mdl-32265057

17.

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

O'Malley, David M; Matulonis, Ursula A; Birrer, Michael J; Castro, Cesar M; Gilbert, Lucy; Vergote, Ignace; Martin, Lainie P; Mantia-Smaldone, Gina M; Martin, Antonio González; Bratos, Raquel; Penson, Richard T; Malek, Karim; Moore, Kathleen N.

Gynecol Oncol ; 157(2): 379-385, 2020 05.

Article in English | MEDLINE | ID: mdl-32081463

18.

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.

Moore, Kathleen N; Birrer, Michael J; Marsters, Jim; Wang, Yulei; Choi, YounJeong; Royer-Joo, Stephanie; Lemahieu, Vanessa; Armstrong, Katy; Cordova, Julie; Samineni, Divya; Schuth, Eva; Vaze, Anjali; Maslyar, Daniel; Humke, Eric W; Hamilton, Erika P; Liu, Joyce F.

Gynecol Oncol ; 158(3): 631-639, 2020 09.

Article in English | MEDLINE | ID: mdl-32534811

19.

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.

Mirza, Mansoor Raza; Åvall Lundqvist, Elisabeth; Birrer, Michael J; dePont Christensen, Rene; Nyvang, Gitte-Bettina; Malander, Susanne; Anttila, Maarit; Werner, Theresa L; Lund, Bente; Lindahl, Gabriel; Hietanen, Sakari; Peen, Ulla; Dimoula, Maria; Roed, Henrik; Ør Knudsen, Anja; Staff, Synnöve; Krog Vistisen, Anders; Bjørge, Line; Mäenpää, Johanna U.

Lancet Oncol ; 20(10): 1409-1419, 2019 10.

Article in English | MEDLINE | ID: mdl-31474354

20.

Biomarkers in ovarian cancer: To be or not to be.

Arend, Rebecca; Martinez, Alba; Szul, Tomasz; Birrer, Michael J.

Cancer ; 125 Suppl 24: 4563-4572, 2019 12 15.

Article in English | MEDLINE | ID: mdl-31967683

Virtual Health Library

United States - Mexico Border

Your selection (0)

Export format:

Export:

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

Inhibition of Kpnß1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.

Biomarkers in ovarian cancer: To be or not to be.